Alberto F. Sobrero, MD, of the Ospedale San Martino, discusses final results of the IDEA study, which supported the use of 3 months of adjuvant CAPOX, vs 6 months, for most patients with stage III colon cancer. The shorter treatment duration reduced toxicity, inconvenience, and cost (Abstract 4004).
Howard A. Burris III, MD, FACP, FASCO, Immediate Past President of ASCO and current Society Board Chair, talks about how the meeting went, with its record-breaking attendance and new format.
Roy S. Herbst, MD, PhD, of Yale Cancer Center, discusses data from the ADAURA study, which showed that compared with placebo, osimertinib as adjuvant therapy after complete tumor resection reduced the risk of disease recurrence or death by 79% in patients with non–small cell lung cancer (Abstract LBA5).
Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute, discusses three important studies focusing on newer therapies for patients with recurrent platinum-sensitive, platinum-agnostic, and advanced recurrent ovarian cancers (Abstracts 6003, 6004, and 6005).
Mikkael A. Sekeres, MD, of the Cleveland Clinic, discusses data from a phase II study of pevonedistat plus azacitidine vs azacitidine alone in patients with higher-risk myelodysplastic syndromes, chronic myelomonocytic leukemia, or low-blast acute myeloid leukemia (Abstract 7506).
Meletios A. Dimopoulos, MD, of the University of Athens, discusses phase III results from the BOSTON trial, which showed that once-weekly selinexor, bortezomib, and dexamethasone significantly improved progression-free survival and overall response rates compared with twice-weekly bortezomib and dexamethasone in patients previously treated for multiple myeloma (Abstract 8501).
